SAGE vs. HALO

Last updated Apr 2, 2026

Compare and contrast key facts about Sage Therapeutics, Inc. (SAGE) and Halozyme Therapeutics, Inc. (HALO).

Performance

SAGE vs. HALO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sage Therapeutics, Inc. (SAGE) and Halozyme Therapeutics, Inc. (HALO). The values are adjusted to include any dividend payments, if applicable.

SAGE vs. HALO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SAGE Sage Therapeutics, Inc.	0.00%	59.85%	-74.94%	-43.18%	-10.34%	-50.83%	19.84%	-24.64%	-41.84%	222.58%
HALO Halozyme Therapeutics, Inc.	-2.82%	40.77%	29.36%	-35.04%	41.51%	-5.85%	140.89%	21.19%	-27.79%	105.06%

Fundamentals

Market Cap SAGE : $543.46M HALO : $7.70B
EPS SAGE : -$4.81 HALO : $2.61
PS Ratio SAGE : 7.72 HALO : 5.68
PB Ratio SAGE : 1.47 HALO : 157.65
Total Revenue (TTM) SAGE : $70.41M HALO : $1.40B
Gross Profit (TTM) SAGE : $63.04M HALO : $1.17B
EBITDA (TTM) SAGE : -$302.71M HALO : $590.37M

Returns By Period

SAGE

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

HALO

• 1D: 1.19%
• 1M: -6.37%
• YTD: -2.82%
• 6M: -12.73%
• 1Y: 5.71%
• 3Y*: 19.64%
• 5Y*: 9.04%
• 10Y*: 20.96%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SAGE vs. HALO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO

HALO Risk / Return Rank: 43
HALO Sharpe Ratio Rank: 45
HALO Sortino Ratio Rank: 40
HALO Omega Ratio Rank: 43
HALO Calmar Ratio Rank: 42
HALO Martin Ratio Rank: 43

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SAGE vs. HALO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sage Therapeutics, Inc. (SAGE) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	SAGE	HALO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.13	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.23	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.48	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.23	—

Correlation

The correlation between SAGE and HALO is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SAGE vs. HALO - Dividend Comparison

Neither SAGE nor HALO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	SAGE	HALO	Difference
Max Drawdown Largest peak-to-trough decline	—	-74.26%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-31.69%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-49.06%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-49.06%	—
Current Drawdown Current decline from peak	—	-19.49%	—
Average Drawdown Average peak-to-trough decline	—	-32.02%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	14.78%	—

Volatility

Volatility by Period

	SAGE	HALO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.11%	—
Volatility (6M) Calculated over the trailing 6-month period	—	23.48%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	43.82%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	39.51%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	43.38%	—

Financials